Book a Meeting

Non-Fucosylated Anti-Human CD19 (GBR 401) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1794ZP) Datasheet

Target
CD19
Isotype
Humanized IgG1
Description
The ADCC-enhanced antibody is a glycosylation-modified therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of fucosylation level. By reducing or removing the fucose of the Fc region, we obtained the ADCC-enhanced antibody, which showed increased binding affinity to the FcyR receptor on immune effector cells in an in vitro ADCC assay compared to its patent fucosylated antibody.

More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 molecule
Background
Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Alternative Names
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Gene ID
930
Trade name
GBR 401
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Host
Humanized afucosylated
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

Related Products

Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ10] (CAT#: BioBet-010ZP)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ102] (CAT#: BioBet-102ZP)
ADCC-Enhanced Anti-Human CD19 (Tafasitamab) Antibody, a biobetter (CAT#: BioBet-CB-003LX)
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody, a biobetter (CAT#: BioBet-CB-030LX)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ101] (CAT#: BioBet-101ZP)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ104] (CAT#: BioBet-104ZP)
Highly Galactosylated Anti-CD19 SGN-CD19A(Denintuzumab mafodotin), a Biobetter Antibody (CAT#: BioBet-GA-105ZP)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ103] (CAT#: BioBet-103ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany